A Trial to Compare the Injection Site Pain Experience of 0.25 mg Semaglutide B and Semaglutide D Administered SC
Latest Information Update: 21 Jan 2021
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity; Overweight; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
Most Recent Events
- 10 Jan 2020 Status changed from recruiting to completed.
- 05 Nov 2019 New trial record
- 01 Nov 2019 Planned End Date changed from 10 Jan 2020 to 5 Jan 2020.